Bayer’s Cash Flow Squeeze: Legal Bills Weigh Heavily as Supreme Court Date Nears

Bayer shareholders endured a rough session on Friday as the stock shed nearly 3% to close at €38.87, despite management’s assurances that a capital increase is off the table. The selloff came during the company’s annual general meeting, where CEO Bill Anderson faced a restive audience over the group’s mounting legal liabilities and a bleak cash flow outlook.

The German pharmaceuticals-to-agrochemicals giant is staring down a year of heavy cash outflows. Anderson confirmed that the company expects to shell out roughly €5 billion this year to settle US litigation, primarily related to glyphosate-based weedkiller claims. That burden will push free cash flow deeply into negative territory in 2026, a stark warning that rattled investors even as the stock remains up more than 70% year-to-date.

Restructuring on a Knife-Edge

Anderson used the shareholder gathering to double down on his radical overhaul of the group’s operating model. Since launching the efficiency drive, Bayer has shed around 14,000 jobs, with 4,700 cuts made in the last year alone. The target remains to slash operational costs by €2 billion by year-end. Supervisory board chairman Norbert Winkeljohann added pressure from the top, demanding sharper profitability from the agriculture division and a stronger pharmaceutical pipeline.

To ensure continuity through the upheaval, the board extended Anderson’s contract early through spring 2029. Stefan Oelrich retains his current board role, while Judith Hartmann will take over as finance chief in June, replacing Wolfgang Nickl as he moves into retirement.

Should investors sell immediately? Or is it worth buying Bayer?

The Legal Calendar Looms Large

All eyes are now turning to the US Supreme Court, which will hear oral arguments in the Durnell case on April 27. A favorable ruling could halt a wave of lawsuits over missing warning labels, potentially capping Bayer’s exposure. Meanwhile, a Missouri judge has already given preliminary approval to a class settlement worth $7.25 billion.

Total provisions for legal risks now stand at €11.8 billion, a staggering sum that forced the board to propose the statutory minimum dividend of just €0.11 per share for 2025. The company ended last year with a net financial debt of €29.8 billion, down from prior levels but still a heavy anchor on the balance sheet.

Analysts See Light, But Caution Rules

Barclays analyst Charles Pitman-King maintains a buy rating on Bayer shares with a €48 price target, arguing the glyphosate saga will eventually find a resolution. He warns, however, that the Supreme Court hearing will inject short-term volatility into the stock.

The next major fundamental checkpoint comes on May 12, when Bayer publishes its first-quarter results. Until then, the shares are likely to remain hostage to legal headlines and the market’s mood on the restructuring’s progress.